company background image
NIPH

Nile for Pharmaceuticals and Chemical IndustriesCASE:NIPH Stock Report

Market Cap

ج.م289.4m

7D

0%

1Y

-4.8%

Updated

26 Oct, 2021

Data

Company Financials
NIPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends2/6

NIPH Overview

The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East.

Price History & Performance

Summary of all time highs, changes and price drops for Nile for Pharmaceuticals and Chemical Industries
Historical stock prices
Current Share Priceج.م28.58
52 Week Highج.م27.50
52 Week Lowج.م50.99
Beta0.35
1 Month Change-7.93%
3 Month Change-23.34%
1 Year Change-4.83%
3 Year Change177.48%
5 Year Change210.99%
Change since IPO91.38%

Recent News & Updates

Shareholder Returns

NIPHEG PharmaceuticalsEG Market
7D0%-5.4%3.0%
1Y-4.8%-1.9%12.4%

Return vs Industry: NIPH underperformed the EG Pharmaceuticals industry which returned -1.9% over the past year.

Return vs Market: NIPH underperformed the EG Market which returned 12.4% over the past year.

Price Volatility

Is NIPH's price volatile compared to industry and market?
NIPH volatility
NIPH Beta0.35
Industry Beta0.84
Market Beta1

Stable Share Price: NIPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: NIPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962n/aOsama Mustafa Basithttps://www.nilepharma.com.eg

The Nile Co. for Pharmaceuticals and Chemical Industries develops, produces, and sells pharmaceutical products primarily in the Middle East. The company offers prescription pharmaceutical products, including tablets, capsules, dry syrups, syrups and suspensions, ointments, gels and creams, suppositories, ampoules, drops, parenteral, sachets, biotechnological products, lyophilized products, sterile antibiotic vials, lotions, shampoos, and solutions. It also provides non-prescription pharmaceutical products, such as analgesic and anti-inflammatory, antihistaminic, anthelmintic, antibacterial, antifungal, cardiovascular disorders, central nervous system and antiparkinsonism drugs, oral cavity products, respiratory system disorders, urinary tract disorders, endocrine glands disorders, gastrointestinal tract disorders, muscle relaxants, topical otic and nasal preparations, topical ophthalmological preparations, dermatological preparations, women and men healthcare products, osteoporosis, pediatrics, cosmetics, antiseptics, and immunological products, as well as vitamins and minerals.

Nile for Pharmaceuticals and Chemical Industries Fundamentals Summary

How do Nile for Pharmaceuticals and Chemical Industries's earnings and revenue compare to its market cap?
NIPH fundamental statistics
Market Capج.م289.37m
Earnings (TTM)ج.م64.42m
Revenue (TTM)ج.م755.51m

4.5x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NIPH income statement (TTM)
Revenueج.م755.51m
Cost of Revenueج.م554.43m
Gross Profitج.م201.08m
Expensesج.م136.66m
Earningsج.م64.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)6.36
Gross Margin26.62%
Net Profit Margin8.53%
Debt/Equity Ratio11.7%

How did NIPH perform over the long term?

See historical performance and comparison

Dividends

7.9%

Current Dividend Yield

35%

Payout Ratio

Valuation

Is Nile for Pharmaceuticals and Chemical Industries undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NIPH (EGP28.58) is trading below our estimate of fair value (EGP105.38)

Significantly Below Fair Value: NIPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NIPH is good value based on its PE Ratio (4.5x) compared to the EG Pharmaceuticals industry average (5.9x).

PE vs Market: NIPH is good value based on its PE Ratio (4.5x) compared to the EG market (11.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NIPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NIPH is good value based on its PB Ratio (0.8x) compared to the EG Pharmaceuticals industry average (1.3x).


Future Growth

How is Nile for Pharmaceuticals and Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nile for Pharmaceuticals and Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Nile for Pharmaceuticals and Chemical Industries performed over the past 5 years?

46.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NIPH has high quality earnings.

Growing Profit Margin: NIPH's current net profit margins (8.5%) are lower than last year (11.5%).


Past Earnings Growth Analysis

Earnings Trend: NIPH's earnings have grown significantly by 46% per year over the past 5 years.

Accelerating Growth: NIPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: NIPH had negative earnings growth (-31%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).


Return on Equity

High ROE: NIPH's Return on Equity (17.3%) is considered low.


Financial Health

How is Nile for Pharmaceuticals and Chemical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: NIPH's short term assets (EGP604.3M) exceed its short term liabilities (EGP345.0M).

Long Term Liabilities: NIPH's short term assets (EGP604.3M) exceed its long term liabilities (EGP3.8M).


Debt to Equity History and Analysis

Debt Level: NIPH's debt to equity ratio (11.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if NIPH's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: NIPH's debt is well covered by operating cash flow (183.1%).

Interest Coverage: NIPH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Nile for Pharmaceuticals and Chemical Industries's current dividend yield, its reliability and sustainability?

7.87%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: NIPH's dividend (7.87%) is higher than the bottom 25% of dividend payers in the EG market (2.63%).

High Dividend: NIPH's dividend (7.87%) is low compared to the top 25% of dividend payers in the EG market (7.87%).


Stability and Growth of Payments

Stable Dividend: NIPH has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: NIPH's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (35.4%), NIPH's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Osama Mustafa Basit

no data

Tenure

Dr. Osama Mustafa Abdul Basit serves as Chairman and Managing Director of The Nile Co. for Pharmaceuticals and Chemical Industries.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

The Nile Co. for Pharmaceuticals and Chemical Industries's employee growth, exchange listings and data sources


Key Information

  • Name: The Nile Co. for Pharmaceuticals and Chemical Industries
  • Ticker: NIPH
  • Exchange: CASE
  • Founded: 1962
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م289.373m
  • Shares outstanding: 10.13m
  • Website: https://www.nilepharma.com.eg

Location

  • The Nile Co. for Pharmaceuticals and Chemical Industries
  • Al-Sawah square
  • ElAmeria
  • Cairo
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:14
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.